P. C. Taylor, E. C. Keystone, D. Van-der-heijde, M. E. Weinblatt, C. Morales et al., Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis, New England Journal of Medicine. 16 févr, vol.376, issue.7, pp.652-62, 2017.

M. Dougados, D. Van-der-heijde, Y. Chen, M. Greenwald, E. Drescher et al., Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study. Annals of the Rheumatic Diseases, vol.76, pp.88-95, 2017.

R. Fleischmann, M. Schiff, D. Van-der-heijde, C. Ramos-remus, A. Spindler et al., Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease-Modifying Antirheumatic Drug Treatment, Arthritis Rheumatol. mars, vol.69, issue.3, pp.506-523, 2017.

S. B. Cohen, Y. Tanaka, M. X. Curtis, J. R. Lee, E. B. Nash et al., Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials, Ann Rheum Dis. juill, vol.76, issue.7, pp.1253-62, 2017.

J. S. Smolen, M. C. Genovese, T. Takeuchi, D. L. Hyslop, W. L. Macias et al., Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment, The Journal of Rheumatology. janv, vol.46, issue.1, pp.7-18, 2019.

J. S. Smolen, D. Aletaha, and I. B. Mcinnes, Rheumatoid arthritis. The Lancet, vol.388, pp.2023-2061, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01890959

J. A. Singh, K. G. Saag, S. L. Bridges, E. A. Akl, R. R. Bannuru et al., American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis: ACR RA TREATMENT RECOMMENDATIONS, Arthritis & Rheumatology. janv, vol.68, issue.1, pp.1-26, 2015.

B. Combe, R. Landewe, C. I. Daien, C. Hua, D. Aletaha et al., 2016 update of the EULAR recommendations for the management of early arthritis, Annals of the Rheumatic Diseases. juin, vol.76, issue.6, pp.948-59, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01794370

J. S. Smolen, R. Landewé, F. C. Breedveld, M. Buch, G. Burmester et al., EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update, Annals of the Rheumatic Diseases. 1 mars, vol.73, issue.3, pp.492-509, 2014.

J. D. Clark, M. E. Flanagan, and J. Telliez, Discovery and Development of Janus Kinase (JAK) Inhibitors for Inflammatory Diseases: Miniperspective, Journal of Medicinal Chemistry. 26 juin, vol.57, issue.12, pp.5023-5061, 2014.

J. S. Smolen, R. Landewé, J. Bijlsma, G. Burmester, K. Chatzidionysiou et al., EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Annals of the Rheumatic Diseases, vol.76, pp.960-77, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01778213

G. R. Burmester, R. Blanco, C. Charles-schoeman, J. Wollenhaupt, C. Zerbini et al., CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. The Lancet, févr, vol.381, issue.9865, pp.451-60, 2013.

R. Fleischmann, J. Kremer, J. Cush, H. Schulze-koops, C. A. Connell et al., Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis, New England Journal of Medicine. 9 août, vol.367, issue.6, pp.495-507, 2012.

J. Kremer, Z. Li, S. Hall, R. Fleischmann, M. Genovese et al., Tofacitinib in Combination With Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis: A Randomized Trial, Ann Intern Med. 20 août, vol.159, issue.4, p.253, 2013.

E. B. Lee, R. Fleischmann, S. Hall, B. Wilkinson, J. D. Bradley et al., Tofacitinib versus Methotrexate in Rheumatoid Arthritis, New England Journal of Medicine. 19 juin, vol.370, issue.25, pp.2377-86, 2014.

D. Van-der-heijde, Y. Tanaka, R. Fleischmann, E. Keystone, J. Kremer et al., CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve-month data from a twenty-four-month phase III randomized radiographic study, Arthritis & Rheumatism. mars, vol.65, issue.3, pp.559-70, 2013.

R. F. Van-vollenhoven, R. Fleischmann, S. Cohen, E. B. Lee, G. Meijide et al., Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis, New England Journal of Medicine. 9 août, vol.367, issue.6, pp.508-527, 2012.

P. C. Taylor, E. C. Keystone, D. Van-der-heijde, M. E. Weinblatt, C. Morales et al., Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis, New England Journal of Medicine. 16 févr, vol.376, issue.7, pp.652-62, 2017.

M. C. Genovese, J. Kremer, O. Zamani, C. Ludivico, M. Krogulec et al., Baricitinib in Patients with Refractory Rheumatoid Arthritis, New England Journal of Medicine. 31 mars, vol.374, issue.13, pp.1243-52, 2016.

M. Dougados, D. Van-der-heijde, Y. Chen, M. Greenwald, E. Drescher et al., Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study. Annals of the Rheumatic Diseases, vol.76, pp.88-95, 2017.

R. Fleischmann, M. Schiff, D. Van-der-heijde, C. Ramos-remus, A. Spindler et al., Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease-Modifying Antirheumatic Drug Treatment, Arthritis Rheumatol. mars, vol.69, issue.3, pp.506-523, 2017.

J. Wollenhaupt, E. Lee, J. R. Curtis, J. Silverfield, K. Terry et al., Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study, Arthritis Res Ther, 2019.

H. Yamanaka, Y. Tanaka, T. Takeuchi, N. Sugiyama, H. Yuasa et al., Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, Japanese patients with rheumatoid arthritis: an open-label, long-term extension study. Arthritis Research & Therapy [Internet]. déc 2016, vol.18

S. B. Cohen, Y. Tanaka, M. X. Curtis, J. R. Lee, E. B. Nash et al., Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials, Ann Rheum Dis. juill, vol.76, issue.7, pp.1253-62, 2017.

J. S. Smolen, M. C. Genovese, T. Takeuchi, D. L. Hyslop, W. L. Macias et al., Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment, The Journal of Rheumatology. janv, vol.46, issue.1, pp.7-18, 2019.

M. Harigai, Growing evidence of the safety of JAK inhibitors in patients with rheumatoid arthritis, Rheumatology. 1 févr, vol.58, issue.Supplement_1, pp.34-42, 2019.

K. L. Winthrop, H. Yamanaka, H. Valdez, E. Mortensen, R. Chew et al., Herpes Zoster and Tofacitinib Therapy in Patients With Rheumatoid Arthritis. Arthritis Rheumatol, vol.66, pp.2675-84, 2014.

Z. Zhang, W. Deng, Q. Wu, and L. Sun, Tuberculosis, hepatitis B and herpes zoster in tofacitinibtreated patients with rheumatoid arthritis, Immunotherapy. mars, vol.11, issue.4, pp.321-354, 2019.

P. C. Taylor, M. E. Weinblatt, G. R. Burmester, T. P. Rooney, S. Witt et al., Cardiovascular Safety During Treatment with Baricitinib in Rheumatoid Arthritis, Arthritis & Rheumatology, 2019.

C. Qiu, X. Zhao, L. She, Z. Shi, Z. Deng et al., Baricitinib induces LDL-C and HDL-C increases in rheumatoid arthritis: a meta-analysis of randomized controlled trials. Lipids in Health and Disease, Disponible sur, vol.18

D. Aletaha, T. Neogi, A. J. Silman, J. Funovits, D. T. Felson et al., Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative, Arthritis Rheum. sept, vol.62, issue.9, pp.2569-81, 2010.
URL : https://hal.archives-ouvertes.fr/hal-01557559

J. R. Curtis, F. Xie, H. Yun, S. Bernatsky, and K. L. Winthrop, Real-World Comparative Risks of Herpes Virus Infections in Tofacitinib and Biologic-Treated Rheumatoid Arthritis Patients, Ann Rheum Dis, vol.75, issue.10, pp.1843-1850, 2016.

E. B. Lee, H. Yamanaka, Y. Liu, W. Tsai, C. Chen et al., Efficacy and safety of tofacitinib for the treatment of rheumatoid arthritis in patients from the Asia-Pacific region: Post-hoc analyses of pooled clinical study data, Int J Rheum Dis. juin, vol.22, issue.6, pp.1094-106, 2019.

L. Carmona, C. Hernández-garcía, C. Vadillo, E. Pato, A. Balsa et al., Increased risk of tuberculosis in patients with rheumatoid arthritis, The Journal of Rheumatology. 1 juill, vol.30, issue.7, pp.1436-1445, 2003.

A. Souto, J. R. Maneiro, E. Salgado, L. Carmona, and J. J. Gomez-reino, Risk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib: a systematic review and meta-analysis of randomized controlled trials and long-term extension studies, Rheumatology. oct, vol.53, issue.10, pp.1872-85, 2014.

E. V. Arkema, J. Jonsson, E. Baecklund, J. Bruchfeld, N. Feltelius et al., Are patients with rheumatoid arthritis still at an increased risk of tuberculosis and what is the role of biological treatments?, Annals of the Rheumatic Diseases. 1 juin, vol.74, issue.6, pp.1212-1219, 2015.

L. Baronnet, T. Barnetche, V. Kahn, C. Lacoin, C. Richez et al., Incidence of tuberculosis in patients with rheumatoid arthritis. A systematic literature review, Joint Bone Spine. mai, vol.78, issue.3, pp.279-84, 2011.

W. Chung, C. Peng, C. Lin, Y. Chang, Y. Chen et al., Rheumatoid arthritis increases the risk of deep vein thrombosis and pulmonary thromboembolism: a nationwide cohort study, Annals of the Rheumatic Diseases, vol.73, issue.10, pp.1774-80, 2014.

R. J. Desai, A. Pawar, M. E. Weinblatt, and S. C. Kim, Comparative Risk of Venous Thromboembolism in Rheumatoid Arthritis Patients Receiving Tofacitinib Versus Those Receiving Tumor Necrosis Factor Inhibitors: An Observational Cohort Study, Arthritis & Rheumatology, vol.71, issue.6, pp.892-900, 2019.

R. Fleischmann, E. Mysler, S. Hall, A. J. Kivitz, R. J. Moots et al., Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis